What can we learn from phase II adjuvant trials in melanoma?

U. Keilholz
, S. Suciu
, A. M.M. Eggermont

Research output: Contribution to journal › Editorial

1 Citation (Scopus)

Original language	English
Pages (from-to)	6-7
Number of pages	2
Journal	British journal of cancer
Volume	83
Issue number	1
DOIs	https://doi.org/10.1054/bjoc.2000.1277
Publication status	Published - 2000
Externally published	Yes

Access to Document

10.1054/bjoc.2000.1277

Cite this

@article{c502f50ab63344d289d7f4c17a9782e2,

title = "What can we learn from phase II adjuvant trials in melanoma?",

author = "U. Keilholz and S. Suciu and Eggermont, \{A. M.M.\}",

year = "2000",

doi = "10.1054/bjoc.2000.1277",

language = "English",

volume = "83",

pages = "6--7",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - What can we learn from phase II adjuvant trials in melanoma?

AU - Keilholz, U.

AU - Suciu, S.

AU - Eggermont, A. M.M.

PY - 2000

Y1 - 2000

UR - https://www.scopus.com/pages/publications/0034121948

U2 - 10.1054/bjoc.2000.1277

DO - 10.1054/bjoc.2000.1277

M3 - Editorial

C2 - 10883660

AN - SCOPUS:0034121948

SN - 0007-0920

VL - 83

SP - 6

EP - 7

JO - British journal of cancer

JF - British journal of cancer

IS - 1

ER -